Clinical Trials

Sanofi Highlights Data from P-II Trial of Rilzabrutinib to Treat Moderate-to-Severe Asthma at ATS 2024

Sanofi Highlights Data from P-II Trial of Rilzabrutinib to Treat Moderate-to-Severe Asthma at ATS 2024

Shots: The P-II PoC trial evaluates rilzabrutinib's (800mg & 1200mg, QD) s...

IRLAB Initiates Dosing with IRL757 in the P-I Study for Apathy

IRLAB Initiates Dosing with IRL757 in the P-I Study for Apathy

Shots: IRLAB has begun dosing with IRL757 in the P-I trial assessing safety, toler...

GSK Reports Results from the P-III (SWIFT-1 and SWIFT-2) Studies of Depemokimab for Treating Severe Asthma

GSK Reports Results from the P-III (SWIFT-1 and SWIFT-2) Studies of Depemokimab for Treating Severe Asthma

Shots: The P-III trials for depemokimab in severe asthma includes SWIFT-1, SWIFT-2...

Sanofi Highlights Data from the P-III (NOTUS) Study of Dupixent for COPD at ATS 2024 and Publishes in the NEJM

Sanofi Highlights Data from the P-III (NOTUS) Study of Dupixent for COPD at ATS 2024 and Publishes in the NEJM

Shots: The P-III (NOTUS) trial assessed Dupixent's (n=470) safety & effica...

Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

Shots: The P-IIa (AIR) study assessed the safety, tolerability & efficacy of b...

Image